Triple Marker Screen - ELISA
The quantitative determination of Alpha-Fetoprotein (AFP), β-Human Chorionic Gonadotropin (hCG) and Unconjugated Estriol (uE3) concentrations in human serum or plasma by a microplate enzyme immunoassay, colorimetric.
Part #: Refer to the IFUs
Manufacturers:
Description
Triple Marker Screening is a prenatal screening test used to identify pregnancies that may be at increased risk for congenital disorders such as Down syndrome (Trisomy 21), Trisomy 18 and open neural tube defects like spina bifida. Based on the screening results, further confirmatory diagnostic procedures such as detailed fetal ultrasound, amniocentesis, followed by karyotyping and F.I.S.H. analysis may be recommended.
The Triple Screen VAST kit measures three key biochemical markers from a single maternal blood sample: Alpha-fetoprotein (AFP), Human Chorionic Gonadotropin (hCG) and Unconjugated Estriol (uE3). Monitoring the levels of these markers during pregnancy is essential for assessing fetal development and overall fetal well-being. The combined interpretation of AFP, hCG and uE3 provides clinicians with a comprehensive overview of both fetal health and maternal condition.
Clinical information and laboratory results obtained using the Triple Screen VAST kit are analyzed collectively and interpreted using established scientific algorithms to estimate the probability and risk of specific congenital abnormalities.
Technical specifications
| Analyte | Principle | Calibrator Concentration | Measurement Range | Assay Time |
| AFP | Sandwich assay | 0, 10, 25, 75, 150, 400 ng/mL | 1 – 400 ng/mL | 75 minutes |
| hCG | Sandwich assay | 0, 10, 25, 50, 100, 250 mIU/mL | 0.8 – 250 mIU/mL | 75 minutes |
| uE3 | Competitive assay | 0, 0.5, 1, 2.5, 10, 20 ng/mL | 0.115 – 20 ng/mL | 75 minutes |
Refer to the product Instruction-For-Use (IFU) for complete details.